Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.
New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.
Based on the results of the SANDPIPER study in advanced, PIK3CA-mutated breast cancer, Genentech has decided not to advance development of the PI3 kinase inhibitor taselisib.
A new study finds that a shorter treatment course might work just as well as a longer one for women with early-stage HER2-positive breast cancer, NPR says.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.
A meta-analysis based on genotyping data for more than 400,000 people with or without the disease led to 17 new risk loci mined for candidate genes
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.